Clinical trials: Obesity, Severe
- Condition Obesity, Severe
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Obesity
Study Examining The Effect Of Renal Impairment On Safety, Toleration And How The Body Processes An Experimental Drug
CP-945,598 is eliminated following extensive metabolism. For some drugs, decreased renal (kidney) function can affect their elimination from the body via metabolism.
- Trial name
- NCT00472836
- Testing
- CP-945,598
- Where
- 2 sites in United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Pfizer
Obesity, Morbid Obesity
Effects of RM-493 on Energy Expenditure in Obese Individuals
Background: RM-493 is a drug that stimulates parts of the brain that control eating and metabolism. It has helped to reduce body weight and improve insulin sensitivity in lab tests.
- Trial name
- NCT01867437
- Testing
- RM-493
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Rhythm Pharmaceuticals, Inc.
End Stage Renal Disease, Renal Impairment
A Study to Evaluate the Impact of Renal Impairment on the Pharmacokinetics (PK) of Ribupatide
The primary objective of the study is to estimate the PK parameters of ribupatide in participants with severe renal impairment or end-stage kidney disease (ESKD) after a single dose of ribupatide subcutaneous (SC) injection…
- Conditions
- End Stage Renal Disease, Renal Impairment, Obesity, Overweight
- Trial name
- NCT07793929
- Testing
- Ribupatide
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Kailera